Literature DB >> 2409169

Role of tachykinins in neurogenic inflammation.

B Pernow.   

Abstract

Recent observations on the distribution, release, and biologic properties of neuropeptides connected to sensory neurons have added new information about the mechanism of hyperemia, plasma extravasation, and increase in smooth muscle tone induced by sensory nerve stimulation and by mechanical, physical, or chemical stimuli. To date, Substance P (SP) is the best characterized of these peptides. Using the skin, eye, and respiratory tract as experimental models, it has been shown that: 1) SP is widely distributed in primary sensory neurons as well as in afferent sensory fibers in the vagus, 2) SP is released from sensory nerve terminals during antidromic stimulation, 3) local administration of SP mimics the effect of sensory nerve stimulation, and 4) hyperemia, plasma leakage, and smooth muscle contractions, normally induced by nerve stimulation or noxious stimuli, are absent in tissues pretreated with the SP depleting agent capsaicin or with SP antagonists. These findings indicate that peptidergic nerve fibers are involved in the local regulation of blood flow, vascular permeability, and the tone of smooth muscles. In addition, they give new insights in the pathophysiology of hyperreactive disorders and neurogenic inflammation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2409169

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

Review 1.  Without nerves, immunology remains incomplete -in vivo veritas.

Authors:  Andrew J Shepherd; James E G Downing; Jaleel A Miyan
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

Review 2.  The role of chemosensitive afferent nerves and TRP ion channels in the pathomechanism of headaches.

Authors:  Mária Dux; Péter Sántha; Gábor Jancsó
Journal:  Pflugers Arch       Date:  2012-08-09       Impact factor: 3.657

3.  Tachykinins stimulate lipid peroxidation mediated by free radicals in gastrointestinal tract of rat.

Authors:  M Lördal; O Söder; P M Hellström
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

4.  A non-peptide NK1-receptor antagonist, RP 67580, inhibits neurogenic inflammation postsynaptically.

Authors:  S M Moussaoui; F Montier; A Carruette; J C Blanchard; P M Laduron; C Garret
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

5.  Calcitonin gene-related peptide potentiates substance P-induced plasma extravasation in the rat trachea.

Authors:  J J Brokaw; G W White
Journal:  Lung       Date:  1992       Impact factor: 2.584

6.  Cultured human synovial fibroblasts rapidly metabolize kinins and neuropeptides.

Authors:  J M Bathon; D Proud; S Mizutani; P E Ward
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

7.  Neutral endopeptidase (3.4.24.11) in plasma and synovial fluid of patients with rheumatoid arthritis. A marker of disease activity or a regulator of pain and inflammation?

Authors:  M Matucci-Cerinic; A Lombardi; G Leoncini; A Pignone; L Sacerdoti; M G Spillantini; G Partsch
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

8.  Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection.

Authors:  Lia M Haynes; Joelyn Tonkin; Larry J Anderson; Ralph A Tripp
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Substance P-induced granulocyte infiltration in mouse skin: the mast cell-dependent granulocyte infiltration by the N-terminal peptide is enhanced by the activation of vascular endothelial cells by the C-terminal peptide.

Authors:  I Iwamoto; S Tomoe; H Tomioka; S Yoshida
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

10.  The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P.

Authors:  Ralph A Tripp; Azzeddine Dakhama; Les P Jones; Albert Barskey; Erwin W Gelfand; Larry J Anderson
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.